MedPath
Found 62 clinical trials|View Analysis
Sort by:

Invasive Candidiasis in Critical Care

Recruiting
Conditions
Invasive Candidiasis
Interventions
Diagnostic Test: Invasive candidiasis test
Other: Urine sample collection for future research
First Posted Date
2024-06-13
Last Posted Date
2024-06-13
Lead Sponsor
University Hospital Ostrava
Target Recruit Count
100
Registration Number
NCT06456151
Locations
🇨🇿

University Hospital Motol, Prague, Czechia

🇨🇿

University Hospital Ostrava, Ostrava, Moravian-Silesian Region, Czechia

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Phase 2
Recruiting
Conditions
Patients With Candidemia and/or Invasive Candidiasis
Interventions
First Posted Date
2024-01-08
Last Posted Date
2024-11-18
Lead Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Target Recruit Count
40
Registration Number
NCT06194201
Locations
🇨🇳

The First Affiliated Hospital Of University Of South China, Hengyang, Hunan, China

Comparison of Uncomplicated Candidemia Therapy Duration in Children

Not Applicable
Recruiting
Conditions
Invasive Candidiasis
Interventions
Other: therapy duration
First Posted Date
2023-03-10
Last Posted Date
2024-05-07
Lead Sponsor
Arkansas Children's Hospital Research Institute
Target Recruit Count
420
Registration Number
NCT05763251
Locations
🇺🇸

Children's Hospital of Orange County, Orange, California, United States

🇺🇸

Comer Children's Hospital, Chicago, Illinois, United States

🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

and more 8 locations

A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus

Phase 3
Not yet recruiting
Conditions
Invasive Candidiasis
Invasive Aspergillosis
Interventions
Drug: Amphotericin B cholesteryl Sulfate Complex for Injection
First Posted Date
2023-02-01
Last Posted Date
2023-02-01
Lead Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Target Recruit Count
60
Registration Number
NCT05707832
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Evaluate Bioequivalence of Micafungin (50mg/Vial)

Phase 4
Completed
Conditions
Invasive Candidiasis
Interventions
First Posted Date
2022-08-11
Last Posted Date
2022-08-11
Lead Sponsor
Yung Shin Pharm. Ind. Co., Ltd.
Target Recruit Count
14
Registration Number
NCT05496725
Locations
🇨🇳

Taichung Veterans General Hospital, Taichung, Taiwan

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Phase 3
Recruiting
Conditions
Candidemia
Candidiasis, Invasive
Interventions
First Posted Date
2022-06-16
Last Posted Date
2024-12-19
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
450
Registration Number
NCT05421858
Locations
🇺🇸

Washington University School of Medicine, Infectious Diseases Clinical Research Unit, Saint Louis, Missouri, United States

🇺🇸

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

🇺🇸

Houston Methodist Hospital - Texas Medical Center, Houston, Texas, United States

and more 4 locations

Early Identification of Candida in Intra-abdominal Candidiasis

Completed
Conditions
Candidiasis, Invasive
Peritonitis Infectious
Critically Ill
Candida Sepsis
Interventions
Diagnostic Test: calscreener
Other: Metabolic profile
Other: optical microscopy
Other: RTqPCR
First Posted Date
2022-03-03
Last Posted Date
2023-07-17
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
40
Registration Number
NCT05264571
Locations
🇫🇷

Central Hospital, Vandoeuvre les Nancy, France

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

Completed
Conditions
Fungal Infection
Candidiasis
First Posted Date
2022-02-11
Last Posted Date
2024-10-09
Lead Sponsor
Mayo Clinic
Target Recruit Count
87
Registration Number
NCT05235711
Locations
🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Phase 3
Suspended
Conditions
Candidiasis, Invasive
Candidemia
Interventions
Drug: SCY-078
Drug: Fluconazole
Drug: Echinocandin
First Posted Date
2022-01-05
Last Posted Date
2023-11-18
Lead Sponsor
Scynexis, Inc.
Target Recruit Count
220
Registration Number
NCT05178862
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇧🇪

Saint Luc University Hospital, Brussels, Belgium

and more 69 locations

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Phase 3
Recruiting
Conditions
Pneumocystis
Invasive Fungal Disease
Prophylaxis of Invasive Fungal Infections
Mycoses
Fungal Infection
Fungemia
Mold Infection
Aspergillus
Candidemia
Invasive Candidiasis
Interventions
Drug: Rezafungin for Injection
Drug: Posaconazole
Drug: Intravenous Placebo
Drug: Fluconazole
Drug: Trimethoprim-sulfamethoxazole (TMP/SMX)
Drug: Oral Placebo
First Posted Date
2020-04-30
Last Posted Date
2024-07-26
Lead Sponsor
Mundipharma Research Limited
Target Recruit Count
600
Registration Number
NCT04368559
Locations
🇺🇸

Augusta University Medical Center, Augusta, Georgia, United States

🇧🇪

University Hospitals Leuven, Campus Gasthuisberg - UZ Leuven, Leuven, Belgium

🇫🇷

Grenoble Alpes University Hospital Center, Grenoble, France

and more 42 locations
© Copyright 2025. All Rights Reserved by MedPath